In a 78‑kg patient with no risk factors who ingested 5 g of paracetamol (acetaminophen) over a single 24‑hour period, what is the risk of acute toxicity and what management is recommended?

Risk Assessment and Management for 5g Paracetamol Ingestion in 78kg Patient

This patient requires emergency department referral for evaluation and likely N-acetylcysteine (NAC) treatment, as the ingestion of 5g (64 mg/kg) over 24 hours does not meet the threshold for mandatory ED referral in repeated supratherapeutic ingestion, but the single-day pattern and dose warrant assessment for potential acute toxicity.

Understanding the Clinical Scenario

This case presents a challenging gray zone. The patient ingested 5g of paracetamol over a single 24-hour period, which translates to approximately 64 mg/kg for a 78kg individual. This scenario doesn't fit neatly into either acute single-ingestion or classic repeated supratherapeutic ingestion patterns.

Risk Stratification Based on Guidelines

Threshold Analysis

The 2007 ACEP guidelines 1 and 2025 consensus guidelines 2 establish clear thresholds for ED referral:

For single 24-hour period ingestions:

• Threshold requiring ED referral: ≥10g OR ≥200 mg/kg (whichever is less) 1, 2
• This patient's ingestion: 5g (64 mg/kg) - below this threshold

However, critical considerations apply:

• The guidelines state that repeated supratherapeutic ingestions exceeding 4g per 24-hour period can cause hepatotoxicity 1
• For patients with risk factors (chronic alcohol use, malnutrition, enzyme-inducing drugs), the threshold drops to ≥4g or 100 mg/kg per day 1, 2
• The 2025 consensus emphasizes that 5g exceeds the maximum therapeutic daily dose of 4g 2

Recommended Management Algorithm

Immediate Actions

1. Obtain detailed ingestion history:

   • Exact timing of each dose taken
   • Formulation type (immediate vs extended-release)
   • Any co-ingestions
   • Presence of risk factors: chronic alcohol use, prolonged fasting, isoniazid use, malnutrition 1

2. ED referral is recommended because:

   • The dose exceeds maximum therapeutic limits (4g/day) 3, 2
   • Cannot be risk-stratified using Rumack-Matthew nomogram (multiple ingestions over >8 hours) 1
   • Early case series show 30% of acetaminophen overdose admissions involve repeated supratherapeutic ingestions with worse prognosis than acute overdoses 1

At Emergency Department

Initial laboratory evaluation:

• Serum paracetamol concentration (though nomogram cannot be used for risk stratification in this pattern) 1
• AST and ALT levels are critical - these guide treatment decisions 1
• Baseline liver function tests

Treatment decision based on Daly et al. algorithm 1:

• If AST/ALT are normal (<50 IU/L): In the Daly study, no patient with normal AST at presentation developed hepatotoxicity, though 50% received some NAC 1
• If paracetamol concentration ≥10 mg/mL OR any transaminase elevation: Initiate NAC 1
• If AST 50-1,000 IU/L: 15% risk of severe hepatotoxicity - NAC indicated 1
• If AST >1,000 IU/L: Severe hepatotoxicity present - NAC mandatory 1

NAC Administration if Indicated

Use the modern two-bag regimen 4:

• 200 mg/kg over 4 hours
• Then 100 mg/kg over 16 hours
• This has similar efficacy but significantly fewer adverse reactions than the older three-bag regimen

Critical Pitfalls to Avoid

1. Don't dismiss this as "therapeutic dosing" - 5g exceeds the FDA maximum daily dose of 4g 3 and the patient cannot self-monitor for hepatotoxicity development

2. Don't rely on the Rumack-Matthew nomogram - it explicitly cannot be used for ingestions over >8 hours 1

3. Don't assume normal presentation means no risk - hepatotoxicity can develop 24-72 hours post-ingestion, and repeated supratherapeutic ingestions have shown worse outcomes than acute overdoses 1

4. Don't delay if transaminases are elevated - any elevation warrants NAC treatment 1

Risk Context

While this patient's dose is below the mandatory 10g/200mg/kg threshold, the evidence shows:

• Doses "just over 4g per day" have caused hepatotoxicity, hepatic failure, and death in case reports 1
• Mean dosing of 10.6g/day over 34 hours in patients who remained asymptomatic (but 50% received NAC) 1
• The absence of risk factors is reassuring but doesn't eliminate risk entirely

The conservative, evidence-based approach is ED evaluation with laboratory assessment to guide NAC therapy 1, 2. The potential benefit of early NAC (if indicated by labs) far outweighs the minimal risk of evaluation, particularly given that NAC efficacy decreases significantly after 8-10 hours from ingestion 1.